Literature DB >> 1658027

Development of an improved method for measuring neutralizing antibody to rotavirus.

D R Knowlton1, D M Spector, R L Ward.   

Abstract

An improved assay was developed for measuring neutralizing antibody titers against rotaviruses. This procedure used the same initial steps as performed to determine antibody titers by the focus reduction neutralization (FRN) assay. However, instead of counting infected cells after staining with fluorescein, reductions in virus infectivity by neutralizing antibody were determined by quantitation of viral antigen production using an ELISA. A linear relationship was found between ELISA absorbance values and focus forming units for each of four prototype rotaviruses, representative of serotypes 1-4. Thus, the serum dilution that resulted in neutralization of 60% of infectious virus (i.e. the neutralizing antibody titer) could be readily determined from absorbance values. Titers found by this method were similar to and as reproducible as those found by the FRN assay. Because this method is less laborious and the results are obtained by objective rather than subjective methods, it represents an improvement over the FRN assay.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658027     DOI: 10.1016/0166-0934(91)90013-p

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  29 in total

1.  Protein-energy malnutrition alters IgA responses to rotavirus vaccination and infection but does not impair vaccine efficacy in mice.

Authors:  Elizabeth A Maier; Kristina J Weage; Marjorie M Guedes; Lee A Denson; Monica M McNeal; David I Bernstein; Sean R Moore
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

2.  Prevention of the murine model of biliary atresia after live rotavirus vaccination of dams.

Authors:  Alexander J Bondoc; Mubeen A Jafri; Bryan Donnelly; Sujit K Mohanty; Monica M McNeal; Richard L Ward; Greg M Tiao
Journal:  J Pediatr Surg       Date:  2009-08       Impact factor: 2.545

3.  Serum rotavirus neutralizing-antibody titers compared by plaque reduction and enzyme-linked immunosorbent assay-based neutralization assays.

Authors:  R L Ward; A Z Kapikian; K M Goldberg; D R Knowlton; M W Watson; R Rappaport
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

4.  Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccine.

Authors:  Timo Vesikari; Aino Karvonen; Ray Borrow; Nick Kitchin; Martine Baudin; Stéphane Thomas; Anne Fiquet
Journal:  Clin Vaccine Immunol       Date:  2011-03-09

5.  Production of reassortant viruses containing human rotavirus VP4 and SA11 VP7 for measuring neutralizing antibody following natural infection.

Authors:  R J Gorrell; R F Bishop
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

6.  Postdose 3 G1 serum neutralizing antibody as correlate of protection for pentavalent rotavirus vaccine.

Authors:  G Frank Liu; Darcy Hille; Susan S Kaplan; Michelle G Goveia
Journal:  Hum Vaccin Immunother       Date:  2017-08-24       Impact factor: 3.452

7.  Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects.

Authors:  Jody Lawrence; Su He; Jason Martin; Florian Schödel; Max Ciarlet; Alexander V Murray
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.

Authors:  Myron J Levin; Jane C Lindsey; Susan S Kaplan; Werner Schimana; Jody Lawrence; Monica M McNeal; Mutsa Bwakura-Dangarembizi; Anthony Ogwu; Evans M Mpabalwani; Paul Sato; George Siberry; Margaret Nelson; Darcy Hille; Geoffrey A Weinberg; Adriana Weinberg
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

9.  Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.

Authors:  Suvi Lappalainen; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

10.  Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children.

Authors:  R L Ward; M M McNeal; D S Sander; H B Greenberg; D I Bernstein
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.